about
Structural basis of the interaction between RalA and Sec5, a subunit of the sec6/8 complexRab14 is involved in membrane trafficking between the Golgi complex and endosomesExo84 and Sec5 are competitive regulatory Sec6/8 effectors to the RalA GTPase.Identification of Rab11 as a small GTPase binding protein for the Evi5 oncogeneMembrane Curvature Protein Exhibits Interdomain Flexibility and Binds a Small GTPaseKinome Screen Identifies PFKFB3 and Glucose Metabolism as Important Regulators of the Insulin/Insulin-like Growth Factor (IGF)-1 Signaling PathwayTBC1D13 is a RAB35 specific GAP that plays an important role in GLUT4 trafficking in adipocytesRab14 is critical for maintenance of Mycobacterium tuberculosis phagosome maturation arrestCross-species gene expression analysis identifies a novel set of genes implicated in human insulin sensitivityCharacterization of the role of the Rab GTPase-activating protein AS160 in insulin-regulated GLUT4 trafficking.Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells.Amplification and demultiplexing in insulin-regulated Akt protein kinase pathway in adipocytes.Site-specific antibody drug conjugates for cancer therapyEmerging role of immunoPET in receptor targeted cancer therapy.Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates.Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteinsDecoupling stability and release in disulfide bonds with antibody-small molecule conjugates.8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET.Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy.Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers.Advancing the careers of life science professionals of Indian origin.Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.An anti-GDNF Family Receptor Alpha 1(GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies.Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload.High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.Development of a semi-automated high throughput transient transfection system.Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice.Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects.Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaCLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemiaCharacterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometryClass I FIPs, Rab11‐Binding Proteins That Regulate Endocytic Sorting and RecyclingInteraction of Guanine Nucleotides with the Signal Recognition Particle fromEscherichia coli†
P50
Q24306783-BC70C944-1EDC-416B-92EE-9A2D7FE6B84FQ24314758-17482424-A220-44EA-92D5-8853677304C8Q24529568-38799424-3D51-403C-9E0D-A60DF0E2AAE6Q24670211-5D983CD0-0E55-4703-B787-F952BBC81850Q27674406-6AA30F6F-4991-47A1-A404-4A68F10E5ED3Q28267012-FC53A345-8790-4ECB-8E94-BD45B81A9C53Q28975624-D1D359FD-38E6-4299-B70E-BD5A1DD20F31Q30478282-DFE68290-D467-434B-9634-A2C71736681EQ33917888-DFEB4EC6-387B-41DF-934D-AD56C27D9A3CQ34449983-8F27088C-467D-4597-BFD9-052FB1778F19Q34884392-8A2950B7-A771-4F3D-8FF0-927DC577EB56Q35838909-FA977E2E-527F-468E-A68C-A63FD1CDE593Q37593705-4E1D1C0B-DB5B-4EB4-81C3-A14B60889C0DQ37804901-FFBD46D4-E531-4E06-A08C-36510AA18ABCQ38949270-2B6E567D-345A-4912-87B1-AEF2473BE2C2Q38959564-936E0392-819A-425C-8E8D-A5D0C658E337Q39090290-B345F338-5F09-4CBB-86FD-3F7FBBF0BC58Q39408093-72D44C34-5C87-48CE-9247-49A594A6F8E6Q39959127-FD6C2225-2ED5-4E25-9511-F44419706A87Q41948460-6B4B7098-0719-42C5-B50B-C10B0C578857Q42314398-89D98318-1735-4C9A-AE1A-B313497BC29CQ42906644-39582C19-5414-4F75-A2F9-E11C6E15257BQ43116972-3F045492-3197-4BBD-82B2-340E66D8F6C1Q43245117-5CC61D55-C9D9-4B04-8D1C-21BA611A7A52Q43516366-3467C41B-7DBB-46BF-8F76-B1DD7D880CD3Q45142454-E9B6D902-043F-4ABC-9F94-85DE40532EF8Q45223731-9F3BBD0B-1DF9-40CF-9126-7BE81B928F13Q47241411-E6DEF79D-6E48-4F21-9A01-79F5EFDD27B1Q48707322-D6613312-3A67-4C7E-A728-0AA7C575460BQ49949111-16C7DC38-EEF7-4DEF-9898-730387A37BD9Q50100291-B9328E25-AE77-4C59-90B9-8019A51A0F76Q51096430-0A2370B4-4B64-458F-AF1C-EB672BEF6F94Q52949558-3A0DF404-12E6-4E36-A944-C5439E242A54Q54454650-9D4D629F-A81E-4BB4-8980-17653C9EAB5DQ56461562-138614C2-759F-4F93-8B7D-DA89DC1DED84Q58237073-38B9E356-9198-4CC2-AC12-6ABD67502DC1Q58237085-AAA8D845-C699-48C6-9A27-D7C5C576E241Q58237105-F4F31B7C-D9B9-471B-B8B5-593AC09D12A7Q58237112-F3CCB8C2-F6F0-4C0B-B3AD-2B7C23D06CA0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jagath R Junutula
@ast
Jagath R Junutula
@en
Jagath R Junutula
@es
Jagath R Junutula
@nl
type
label
Jagath R Junutula
@ast
Jagath R Junutula
@en
Jagath R Junutula
@es
Jagath R Junutula
@nl
prefLabel
Jagath R Junutula
@ast
Jagath R Junutula
@en
Jagath R Junutula
@es
Jagath R Junutula
@nl
P106
P108
P31
P496
0000-0002-5942-4428